Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388635 | 1.00 | HPGD (0.49) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL229558 | 1.00 | HPGD (0.49) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL27554734 | 1.00 | HPGD (0.49) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL2286036 | 1.00 | HPGD (0.49) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL3909230 | 0.98 | HPGD (0.48) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| Methane SCHEMBL28850179 | 0.98 | HPGD (0.48) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| Fluoride SCHEMBL30783508 | 0.98 | HPGD (0.48) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| Hydrogen Sulfide SCHEMBL27481907 | 0.98 | HPGD (0.48) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL5847085 | 0.90 | HPGD (0.50) | HPGDTSHRSMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL30525289 | 0.87 | HDAC3 (0.47) | HPGDTSHRHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090654-B1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LTD (IN) | 2025-07-09 | — | — | EP | claimed |
| CN-114981253-B | Process and intermediates for preparing chroman compounds and methods therefor | 印度鲁宾有限公司 | 2024-06-18 | — | — | CN | claimed |
| US-20230140054-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LIMITED (IN) | 2023-05-04 | — | — | US | claimed |
| CN-114981253-A | Process and intermediates for preparing chroman compounds and methods therefor | 印度鲁宾有限公司 | 2022-08-30 | — | — | CN | claimed |
| WO-2021144814-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-22 | — | — | WO | claimed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-5658796-A | USING ENZYME DERIVED FROM SERRATIA | SEPRACHEM, INC. (US) | 1997-08-19 | — | — | US | claimed |
| WO-1996040975-A1 | OPTICAL RESOLUTION OF ALKYL CHROMAN-2-CARBOXYLATES | SEPRACHEM, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0448254-B1 | Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde | PFIZER (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0448254-A2 | Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde | PFIZER INC. (US) | 1991-09-25 | — | — | EP | claimed |
| JP-4234871-A | — | — | None | — | — | JP | disclosed |
| EP-4090654-B1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LTD (IN) | 2025-07-09 | — | — | EP | disclosed |
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | LUPIN LIMITED (IN) | 2025-07-01 | — | — | US | disclosed |
| CN-114981253-B | Process and intermediates for preparing chroman compounds and methods therefor | 印度鲁宾有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240051931-A1 | HDAC INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-02-15 | — | — | US | disclosed |
| EP-0539803-A1 | Triazospirodecanone-methyl-chromans for the treatment of central nervous system illnesses | BAYER AG (DE) | 1993-05-05 | — | — | EP | disclosed |
| JP-H04234871-A | INTERMEDIATE FOR PRODUCING 2R-BENZYL-CHROMAN-6-CARBALDEHYDE | PFIZER INC | 1992-08-24 | — | — | JP | disclosed |
| US-5089637-A | PROCESS AND INTERMEDIATES FOR 2R-BENZYL-CHROMAN-6-CARBALDEHYDE | PFIZER INC. (US) | 1992-02-18 | — | — | US | disclosed |
| EP-0448254-A2 | Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde | PFIZER INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| EP-0448254-A2 | Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde | PFIZER INC. (US) | 1991-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140054-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | CASR, CALCR, RYR1 | HPGD 2248/4885TSHR 261/4885SMN1; SMN2 2582/4885 |
| US-20240051931-A1 | HDAC INHIBITORS | HDAC8, HDAC1, HDAC2 | HPGD 1902/4885TSHR 2658/4885SMN1; SMN2 587/4885 |
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | CASR, CALCR, RYR1 | HPGD 2248/4885TSHR 261/4885SMN1; SMN2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.